Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 69.00
High: 69.00
Low: 69.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Appoints Medical Director

27 Jul 2016 07:00

RNS Number : 3124F
NetScientific PLC
27 July 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Wanda Names Dr. Suzanne Steinbaum, Renowned Cardiologist and Women's Heart Health Advocate, as Medical Director

 

Dr. Steinbaum joins Wanda's mission to create personalized health guidance and accountability using advanced predictive analytics, behavioural science, and mobile technologies.

 

London, UK - 27 July 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, notes Wanda's announcement of the appointment of Dr. Suzanne Steinbaum, a board-certified cardiologist and well-known national advocate for women's heart health, as Medical Director.

 

Commenting on the news, François R. Martelet, Chief Executive Officer of NetScientific, said: "Dr. Steinbaum's extensive clinical experience and background in cardiology will make her a valuable addition to Wanda's already distinguished team."

 

The full text of the announcement issued by Wanda on 26 July 2016 is as follows:

 

 

 

Dr. Suzanne Steinbaum, Renowned Cardiologist and Women's Heart Health Advocate, Named Medical Director for Wanda

 

Dr. Steinbaum joins Wanda's mission to create personalized health guidance and accountability using advanced predictive analytics, behavioral science, and mobile technologies.

 

SAN FRANCISCO - July 26, 2016 - Wanda, a leading digital health platform dedicated to advancing the effectiveness and efficiency of patient care, today announced that Dr. Suzanne Steinbaum, board-certified cardiologist and well-known national advocate for women's heart health, has joined the company as Medical Director.

 

Dr. Steinbaum is a Fellow of the American College of Cardiology and a Fellow of the American Heart Association, and has been trained in both Cardiology and Preventative Cardiology. She is also a National Spokesperson for the American Heart Association's Go Red for Women campaign and chairs Go Red for Women in New York City. She will lend her world-class expertise and leadership to further Wanda's mission of empowering users to improve their own health through data-driven insights and personalized guidance.

 

"We're thrilled to have Dr. Steinbaum join our distinguished team of data scientists, engineers, and designers to help us focus on tackling mankind's number one killer: heart disease," said Wanda's CEO Steve Curd. "Dr. Steinbaum adds an invaluable amount of clinical competence and a deep understanding of what it takes to keep people at risk of heart disease out of the hospital."

 

Wanda's digital health platform collects critical information from individuals and utilizes machine learning to deliver ongoing risk analysis and decision support. Combined with a smart, inspirational, and engaging interface, Wanda's capabilities enable users to better manage their own cardiovascular health. The result is not only a higher quality of life, but a significant reduction in the cost burden of these individuals.

 

"Wanda is at the forefront of a critical turning point in healthcare, in which patient engagement is essential to successful outcomes," said Dr. Steinbaum. "I have devoted my entire career to the treatment of heart disease through early detection, education, and prevention. The moment I met the Wanda team, I realized our collaboration could provide an incredibly unique force in preventing our country's number one killer. While heart disease is 80 to 90% preventable, lifestyle changes are critical, and this is where Wanda comes in. Wanda's ability to monitor health markers and personalize recommendations to create impactful changes for the individual will ultimately change outcomes."

 

Despite the fact that over 50% of heart-related hospitalizations are avoidable, heart disease remains one of America's most expensive health challenges. Until now, no one has brought together all of the pieces necessary to impact this immense problem at scale, which drives an estimated $100 billion of cost in the US alone.

 

"Instead of treating people as 'passive data sources' to be tested, examined, treated, and often criticized for non-compliance, we believe that the only effective approach is to engage each individual in a meaningful dialog to personalize the experience," says Mark Heinemeyer, CCO for Wanda. "As we learn more about each individual, we can guide them to make more intelligent, accountable decisions affecting their hearts."

 

 

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

 

Tel: +44 (0)20 3514 1800

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

 

About Wanda

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found at www.yourwanda.com.

 

About Dr. Suzanne Steinbaum

Dr. Suzanne Steinbaum is an attending cardiologist and the Director of Women's Heart Health of Lenox Hill Hospital in New York City. She has done fellowship training in both Preventive Cardiology and Cardiology. She recently released her book Dr. Suzanne Steinbaum's Heart Book: Every Woman's Guide to a Heart Healthy Life, teaching all women how to lead the healthiest lives by living from the heart. She is the host of Focus onHealth, a weekly magazine news show spotlighting health topics, seen on WLNYTV. She has been awarded a New York Times Super Doctor, and a Castle and Connolly Top Doctor for Cardiovascular Disease.

 

Dr. Steinbaum is a Fellow of the American College of Cardiology and a Fellow of the American Heart Asssociation in Epidemiology and Prevention. She is a National Spokesperson for the Go Red for Women campaign and chairperson of Go Red for Women in New York City.

 

Dr. Steinbaum has devoted her career to the treatment of heart disease through early detection, education, and prevention. She has lectured nationally on topics of coronary artery disease, women and heart disease, natural and alternative ways of treating heart disease and the prevention of heart disease. She is often cited in magazines and newspapers and is regularly seen on network news health segments for ABC, NBC and CBS, CNN, WPIX and FOX as a leading consultant in the field of women and heart disease, preventive cardiology and topics of lifestyle management. She is regularly interviewed for breaking news in U.S. News and World Report, Healthday and WebMD. She has written on topics of cardiac prevention and nutrition and has been quoted in many publications and magazines, such as Self, Glamour, More, Fitness, The Wall Street Journal and Family Circle. She is a regular contributor to The Huffington Post, Dr. Oz, Bottomline Health, and Sharecare.

 

Her unique perspectives on health, wellness and overall vitality by living a heart-centered life can be found at www.srsheart.com, on Facebook at Dr. Suzanne Steinbaum and Twitter at @DrSteinbaum.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAPGUMUMUPQGQQ
Date   Source Headline
15th Jan 20207:00 amRNSBoard Change
18th Dec 201911:24 amRNSHolding(s) in Company
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
18th Feb 20194:54 pmRNSHolding(s) in Company
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
15th Feb 201912:00 pmRNSConclusion of Strategic Review
14th Feb 201912:07 pmRNSGlycotest Receives First $3m Tranche from Fosun
15th Jan 201911:08 amRNSTermination of Formal Sales Process
15th Jan 20199:37 amRNSForm 8.5 - NetScientific plc
14th Jan 201910:25 amRNSForm 8.5 - NetScientific PLC
8th Jan 201911:58 amRNSForm 8.5 - NetScientific PLC
7th Jan 201910:14 amRNSForm 8.5 - NetScientific PLC
4th Jan 20199:13 amRNSForm 8.5 - NetScientific PLC
31st Dec 20189:36 amRNSForm 8.5 - NetScientific PLC
24th Dec 201810:23 amRNSForm 8.5 - NetScientific PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.